trending Market Intelligence /marketintelligence/en/news-insights/trending/zrrhmllwia9tume8grhj5q2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Biocept to raise $11.6M in rights offering


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Biocept to raise $11.6M in rights offering

Biocept Inc. said it expects to raise $11.6 million from a rights offering that expired Aug. 8.

The offering allowed eligible shareholders to buy a unit of the company for $1,000 each. The unit comprised a series A preferred stock that is convertible into common shares, and 220 warrants, each of which can be used to purchase an additional common stock for $4.53 apiece.

The warrants are exercisable within a five-year period after the issuance date.

The transaction is expected to close Aug. 13, subject to customary closing conditions.

San Diego-based Biocept is a molecular diagnostics company that provides assays for lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

Maxim Group LLC and Dawson James Securities Inc. acted as co-dealer-managers in the offering, with Chardan and WestPark Capital serving as financial advisers.